Bayer Expands MRI System Compatibility with New FDA Clearance

In an exciting development for the radiology field, Bayer has received FDA 510(k) clearance for enhanced capabilities of its MEDRAD® MRXperion Magnetic Resonance Injection System. This advancement broadens the system’s compatibility to support MRI scanners up to the 7 Tesla (7T) range. This expansion increases flexibility and efficiency across various magnetic resonance (MR) environments, promising improved workflow and contrast delivery in clinical imaging.

Bayer’s new clearance exemplifies the company’s commitment to providing integrated, innovative radiology solutions. With MRI systems occupying a pivotal role in healthcare for non-invasive diagnostics, this enhancement is significant for diverse medical settings. The updated system now includes the Imaging Scanner Interface 2 (ISI2), which facilitates efficient synchronization between contrast injections and MR scans. This feature optimizes workflow for radiology professionals and enhances operational efficiency. With a strong track record of delivering reliable imaging performance, the clearance reinforces MRXperion’s position as a versatile solution within Bayer’s comprehensive MR portfolio, which includes contrast media and advanced workflow solutions.

This FDA clearance marks a key step forward in Bayer’s pursuit of enhancing radiology technology and patient care. By expanding the compatibility of its MRXperion Injection System to high-field MRI scanners, Bayer is ensuring that their advanced medical imaging solutions meet the evolving needs of healthcare providers, ultimately aiming to improve patient outcomes across various clinical settings.